GDTC
CytoMed Therapeutics·NASDAQ
--
--(--)
--
--(--)
GDTC fundamentals
During FY 2025, CytoMed Therapeutics (GDTC) reported revenue of 252.26K, a YoY change of 395.88%. Net income was -3.11M, a YoY change of -68.36%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
FY,2019 | H1,2020 | FY,2020 | H1,2021 | FY,2021 | H1,2022 | FY,2022 | H1,2023 | FY,2023 | H1,2024 | FY,2024 | H1,2025 | FY,2025 | TTM |
|---|
Start Date | Jan 1, 2019 | Jan 1, 2020 | Jan 1, 2020 | Jan 1, 2021 | Jan 1, 2021 | Jan 1, 2022 | Jan 1, 2022 | Jan 1, 2023 | Jan 1, 2023 | Jan 1, 2024 | Jan 1, 2024 | Jan 1, 2025 | Jan 1, 2025 | -- |
End Date | Dec 31, 2019 | Jun 30, 2020 | Dec 31, 2020 | Jun 30, 2021 | Dec 31, 2021 | Jun 30, 2022 | Dec 31, 2022 | Jun 30, 2023 | Dec 31, 2023 | Jun 30, 2024 | Dec 31, 2024 | Jun 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 50.87K -- | 122.56K -- | 252.26K +395.88% | 252.26K -- |
Sales and Services Revenue | -- -- | -- -- | 0 -- | -- -- | 0 -- | -- -- | 0 -- | 0 -- | 0 -- | 0 -- | 50.87K -- | 122.56K -- | 252.26K +395.88% | 252.26K -- |
Other Operating Income | -- -- | -- -- | 96.46K -- | -- -- | 111.86K +15.98% | -- -- | 360.55K +222.31% | 210.19K -- | 392.77K +8.94% | 170.62K -18.83% | 341.38K -13.09% | 235.86K +38.24% | 432.24K +26.62% | 432.24K -- |
Operating Expenses | 612.47K -- | 374.99K -- | 1.05M +70.97% | 756.07K +101.62% | 1.39M +32.75% | 762.88K +0.90% | 1.75M +25.56% | 1.77M +132.35% | 1.63M -6.72% | 1.39M -21.85% | 1.95M +19.97% | 1.96M +41.54% | 2.68M +37.08% | 2.68M -- |
Selling, General and Administrative Expenses | 78.05K -- | 70.01K -- | 169.37K +117.01% | 93.29K +33.26% | 201.57K +19.01% | 111.37K +19.38% | 240.53K +19.33% | 165.89K +48.96% | 423.10K +75.91% | 261.18K +57.45% | 542.91K +28.32% | 671.24K +157.00% | 900.04K +65.78% | 900.04K -- |
Selling and Marketing Expenses | -- -- | -- -- | 4.68K -- | -- -- | 1.84K -60.78% | -- -- | 0 -100.00% | 18.02K -- | -- -- | 6.37K -64.63% | -- -- | 9.14K +43.33% | -- -- | -- -- |
Research and Development Expenses | 439.94K -- | 267.48K -- | 785.60K +78.57% | 388.67K +45.31% | 806.67K +2.68% | 434.47K +11.78% | 1.14M +40.83% | 599.95K +38.09% | 1.20M +6.06% | 719.01K +19.84% | 1.40M +16.00% | 913.96K +27.11% | 1.72M +23.38% | 1.72M -- |
Loss on Disposal of Assets | -- -- | -- -- | 0 -- | -- -- | 0 -- | -- -- | -208.89 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Other Operating Expenses | 94.48K -- | 37.51K -- | 92.18K -2.43% | 274.10K +630.78% | 381.87K +314.25% | 217.05K -20.82% | 369.05K -3.36% | 1.01M +363.82% | 0 -100.00% | 405.07K -59.76% | 12.53K -- | 375.44K -7.32% | 52.88K +321.93% | 52.88K -- |
Operating Income | -612.47K -- | -374.99K -- | -950.70K -55.22% | -756.07K -101.62% | -1.28M -34.45% | -762.88K -0.90% | -1.38M -8.34% | -1.56M -104.80% | -1.24M +10.80% | -1.21M +22.26% | -1.56M -26.36% | -1.60M -31.91% | -1.99M -27.68% | -1.99M -- |
Non-Operating Income (Loss) | -20.25K -- | -4.58K -- | -514.13K -2438.57% | -6.14K -34.14% | -239.44K +53.43% | 46.93K +864.05% | -950.11K -296.81% | -33.61K -171.63% | -1.90M -99.67% | 411.41K +1323.96% | -285.01K +84.98% | -163.51K -139.74% | -1.11M -291.18% | -1.11M -- |
Income (Loss) from Affiliates | -- -- | -- -- | 0 -- | -- -- | -157.23K -- | -16.03K -- | -25.03K +84.08% | -14.61K +8.84% | -23.65K +5.51% | 11.76K +180.51% | 10.08K +142.61% | -8.33K -170.86% | -4.97K -149.33% | -4.97K -- |
Income (Loss) from Associates | -- -- | -- -- | 0 -- | -- -- | -157.23K -- | -- -- | -25.03K +84.08% | -14.61K -- | -23.65K +5.51% | 11.76K +180.51% | 10.08K +142.61% | -8.33K -170.86% | -4.97K -149.33% | -4.97K -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -433.95K -- | -- -- | 9.37K +102.16% | -- -- | -813.55K -8784.02% | -73.03K -- | -- -- | 266.29K +464.64% | -- -- | -214.52K -180.56% | -- -- | -- -- |
Gain (Loss) on Foreign Currency Exchange | -- -- | -- -- | -327.68 -- | -- -- | -7.01K -2040.07% | -- -- | -19.71K -181.10% | 60.01K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Other Non-Operating Income (Loss) | -- -- | 24.60K -- | -- -- | 36.72K +49.26% | -- -- | 107.58K +192.94% | -- -- | -- -- | -2.05M -- | -- -- | -512.74K +75.00% | -- -- | -1.19M -132.10% | -1.19M -- |
Net Interest Expense | 20.25K -- | 29.18K -- | 79.85K +294.28% | 42.87K +46.89% | 84.56K +5.90% | 44.62K +4.10% | 91.82K +8.59% | 5.98K -86.59% | -177.70K -293.52% | -133.36K -2329.27% | -217.65K -22.48% | -59.35K +55.50% | -80.09K +63.20% | -80.09K -- |
Interest Expense | 20.25K -- | 29.18K -- | 79.85K +294.28% | 42.87K +46.89% | 87.05K +9.02% | 44.62K +4.10% | 93.39K +7.27% | 30.14K -32.46% | 38.87K -58.38% | 7.24K -75.99% | 14.87K -61.75% | 8.11K +12.04% | 16.26K +9.35% | 16.26K -- |
Interest Income | -- -- | -- -- | 0 -- | -- -- | 2.49K -- | -- -- | 1.56K -37.22% | 24.16K -- | 216.57K +13743.03% | 140.60K +482.01% | 232.52K +7.37% | 67.45K -52.02% | 96.35K -58.56% | 96.35K -- |
Pretax Income From Continuing Operations | -632.72K -- | -379.57K -- | -1.46M -131.51% | -762.21K -100.81% | -1.52M -3.61% | -715.95K +6.07% | -2.33M -53.85% | -1.60M -122.92% | -3.13M -34.15% | -803.23K +49.67% | -1.85M +41.07% | -1.77M -119.83% | -3.11M -68.36% | -3.11M -- |
Income Tax Expense | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 1.22K -- | -- -- | 494.96 -59.55% | -- -- | 0 -100.00% | -- -- | 0 -- | -- -- |
Current Income Tax | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 1.22K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | -632.72K -- | -379.57K -- | -1.46M -131.51% | -762.21K -100.81% | -1.52M -3.61% | -715.95K +6.07% | -2.34M -53.93% | -1.60M -122.92% | -3.13M -34.10% | -803.23K +49.67% | -1.85M +41.08% | -1.77M -119.83% | -3.11M -68.36% | -3.11M -- |
Net Income Attributable to Minority Interests | -- -- | -- -- | -140.76 -- | -95.15 -- | -187.13 -32.94% | -74.8 +21.39% | -181.29 +3.12% | -103.53 -38.41% | -207.69 -14.56% | -107 -3.35% | -3.78K -1719.59% | -1.63K -1419.54% | -12.35K -226.76% | -12.35K -- |
Net Income Attributable to Owners of the Company | -632.72K -- | -379.57K -- | -1.46M -131.49% | -762.11K -100.78% | -1.52M -3.61% | -715.88K +6.07% | -2.34M -53.94% | -1.60M -122.93% | -3.13M -34.10% | -803.13K +49.67% | -1.84M +41.20% | -1.76M -119.65% | -3.10M -68.04% | -3.10M -- |
Net Income Attributable to Common Stockholders | -632.72K -- | -379.57K -- | -1.46M -131.49% | -762.11K -100.78% | -1.52M -3.61% | -715.88K +6.07% | -2.34M -53.94% | -1.60M -122.93% | -3.13M -34.10% | -803.13K +49.67% | -1.84M +41.20% | -1.76M -119.65% | -3.10M -68.04% | -3.10M -- |
Other Comprehensive Income | -1.02K -- | -17.80K -- | -5.01K -390.68% | -19.08K -7.20% | -16.74K -234.28% | -26.76K -40.26% | -72.00K -330.17% | -48.96K -82.96% | -68.16K +5.33% | 3.98K +108.13% | 119.78K +275.75% | -18.43K -563.00% | 102.68K -14.28% | 102.68K -- |
Total Comprehensive Income | -633.74K -- | -397.37K -- | -1.47M -131.93% | -781.29K -96.61% | -1.53M -4.39% | -742.72K +4.94% | -2.41M -56.95% | -1.64M -121.48% | -3.20M -32.92% | -799.25K +51.41% | -1.73M +46.08% | -1.78M -123.23% | -3.01M -74.10% | -3.01M -- |
Total Comprehensive Income Attributable to Minority Interests | -- -- | -- -- | -140.76 -- | -95.15 -- | -187.13 -32.94% | -74.8 +21.39% | -181.29 +3.12% | -103.53 -38.41% | -207.69 -14.56% | -107 -3.35% | -3.78K -1719.59% | -1.63K -1419.54% | -12.35K -226.76% | -12.35K -- |
Total Comprehensive Income Attributable to Owners of the Company | -633.74K -- | -397.37K -- | -1.47M -131.91% | -781.19K -96.59% | -1.53M -4.39% | -742.64K +4.93% | -2.41M -56.95% | -1.64M -121.49% | -3.20M -32.92% | -799.15K +51.41% | -1.72M +46.19% | -1.78M -123.05% | -2.99M -73.76% | -2.99M -- |
Basic EPS | 0 -- | 0 -- | -0.25 -- | -0.12 -- | -0.22 +12.00% | -0.09 +25.00% | -0.3 -36.36% | -0.16 -77.78% | -0.3 -- | -0.07 +56.25% | -0.16 +46.67% | -0.15 -114.29% | -0.26 -62.50% | -0.26 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -0.25 -- | -- -- | -0.22 +12.00% | -- -- | -0.3 -36.36% | -0.16 -- | -0.3 -- | -0.07 +56.25% | -0.16 +46.67% | -- -- | -0.26 -62.50% | -0.26 -- |
Diluted EPS | 0 -- | 0 -- | -0.25 -- | -0.12 -- | -0.22 +12.00% | -0.09 +25.00% | -0.3 -36.36% | -0.16 -77.78% | -0.3 -- | -0.07 +56.25% | -0.16 +46.67% | -0.15 -114.29% | -0.26 -62.50% | -0.26 -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -0.25 -- | -- -- | -0.22 +12.00% | -- -- | -0.3 -36.36% | -0.16 -- | -0.3 -- | -0.07 +56.25% | -0.16 +46.67% | -- -- | -0.26 -62.50% | -0.26 -- |
You can ask Aime
Did CytoMed Therapeutics beat or miss consensus estimates last quarter?What is CytoMed Therapeutics's latest dividend and current dividend yield?What guidance did CytoMed Therapeutics's management provide for the next earnings period?What is the market's earnings forecast for CytoMed Therapeutics next quarter?What is CytoMed Therapeutics's gross profit margin?What is the revenue and EPS growth rate for CytoMed Therapeutics year over year?What does CytoMed Therapeutics do and what are its main business segments?What were the key takeaways from CytoMed Therapeutics’s earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
